The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer
Adult
Aged, 80 and over
0301 basic medicine
Research
Reproducibility of Results
Breast Neoplasms
Kaplan-Meier Estimate
Middle Aged
Prognosis
Ki-67 Antigen
0302 clinical medicine
ROC Curve
Biomarkers, Tumor
Humans
Female
Aged
DOI:
10.1007/s10549-024-07352-4
Publication Date:
2024-05-26T19:01:26Z
AUTHORS (6)
ABSTRACT
Abstract Purpose Quantification of Ki67 in breast cancer is a well-established prognostic and predictive marker, but inter-laboratory variability has hampered its clinical usefulness. This study compares the value reproducibility scoring using four automated, digital image analysis (DIA) methods two manual methods. Methods The cohort consisted 367 patients diagnosed between 1990 2004, with hormone receptor positive, HER2 negative, lymph node negative cancer. Manual was performed predefined criteria. DIA QuPath Visiopharm® platforms. Reproducibility assessed by intraclass correlation coefficient (ICC). ROC curve survival identified optimal cutoff values addition to recommendations International Working Group Norwegian Guidelines. Kaplan–Meier curves, log-rank test Cox regression association distant metastasis (DM) free survival. Results hotspot global showed good agreement when compared their counterpart (ICC > 0.780), excellent different platforms 0.781–0.906). Different cutoffs demonstrate significant DM-free (p < 0.05). had greater for 14% (HR 3.054–4.077) than 2.012–2.056). use single all affected distribution prediction outcomes (e.g. false positives negatives). Conclusion demonstrates that superior methods, further required standardize definition cut-off.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....